Autoimmune Brain Panel™Published Studies
![Translational Psychiatry](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-translational-psychiatry.jpg)
Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism
Published: Translational Psychiatry
Study results suggest that the autoimmune targets in the Panel can predict IVIG treatment response in a subset of autism patients.
![PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-pandas-lyme-neuropysch.jpg)
Case Report: PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms: Treatment, Resolution, and Recovery
PUBLISHED: FRONTIERS IN PSYCHIATRY
A previously asymptomatic, healthy 7-year-old girl experienced an abrupt onset of several physical, neurological, and psychiatric symptoms increasing in intensity over a 3-week period.
![Autoantibody biomarkers for basal ganglia encephalitis in Sydenham chorea and PANDAS](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-frontier-psychiatry.jpg)
Autoantibody biomarkers for basal ganglia encephalitis in Sydenham chorea and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections
PUBLISHED: FRONTIERS IN PSYCHIATRY
Study reviews the utilization of antineuronal antibodies, measured with the Autoimmune Brain Panel™ (formerly known as the Cunningham Panel™), as biomarkers for infection-triggered autoimmune basal ganglia encephalitis and the significance of the CaMKinase II.
![Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-brain-behavior-pub.jpg)
Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
PUBLISHED: BRAIN, BEHAVIOR & IMMUNITY
The Autoimmune Brain Panel™ test results indicate Lyme disease may trigger an autoimmune dysfunction, as study findings indicate elevated neuronal autoantibodies may be associated with persistent symptoms.
![Evaluation of the Panel in PANDAS and PANS](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-panel-evaluation.jpg)
Evaluation of the Panel in PANDAS and PANS: Changes in antineuronal antibody titers parallel changes in patient symptoms
PUBLISHED: JOURNAL OF NEUROIMMUNOLOGY
Study findings support clinical utility of the antineuronal and cell-stimulatory assays comprising the Autoimmune Brain Panel™ as an aid in the diagnosis of an underlying autoimmune etiology in patients with neuropsychiatric symptoms.
![An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment](https://www.moleculera.com/wp-content/uploads/2024/01/lng-cunningham-reports-psychiatry.jpg)
An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment
PUBLISHED: CASE REPORTS IN PSYCHIATRY
Case report: A 15-year-old patient, initially diagnosed with schizophrenia, is tested with the Autoimmune Brain Panel. Results indicate that her symptoms have an autoimmune basis. After receiving proper treatment, she makes a full recovery.